[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fsXctgVjNkoODhLf9dDcX_cBoMi6xrcafB18STY2_4XM":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":8,"nonDrugCount":8,"topConditions":11,"upcomingReadouts":32,"phaseBuckets":33,"rows":40},"Adocia",[4],27,false,0,1,1196,[12,15,18,20,23,26,28,30],{"name":13,"count":14},"Type 1 Diabetes Mellitus",9,{"name":16,"count":17},"Diabetes Mellitus Type 1",4,{"name":19,"count":17},"Type 2 Diabetes Mellitus",{"name":21,"count":22},"Healthy",3,{"name":24,"count":25},"Type 1 Diabetes",2,{"name":27,"count":9},"Type 2 Diabetes",{"name":29,"count":9},"Diabetes",{"name":31,"count":9},"Diabetes Mellitus, Type 1",[],[34,35,36,37,38,39],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[41,67,192,236,264,295,317,335,353,371,389,407,425,460,503,539,565,587,612,630,648,666,684,702,720,738,756,774,797,815,833,860,878,896,914,932,950,974,992,1010,1028,1046,1072,1090,1108,1126,1144,1162],{"intervention":42,"totalTrials":9,"cells":43},"BioChaperone PDGF-BB",{"EARLY_PHASE1":44,"PHASE1":46,"PHASE2":48,"PHASE3":50,"PHASE4":63,"NA":65},{"trials":45,"activeCount":8},[],{"trials":47,"activeCount":8},[],{"trials":49,"activeCount":8},[],{"trials":51,"activeCount":8},[52],{"nctId":53,"briefTitle":54,"status":55,"phases":56,"primaryCompletion":57,"completion":57,"start":58,"enrollment":59,"conditions":60,"interventions":62},"NCT02236793","A Phase 3 Clinical Trial to Assess the Effectiveness of BioChaperone PDGF-BB In the Treatment of Chronic Diabetic Foot Ulcer","COMPLETED",[37],"2016-08","2014-12",252,[61],"Diabetic Foot Ulcer",[42],{"trials":64,"activeCount":8},[],{"trials":66,"activeCount":8},[],{"intervention":68,"totalTrials":69,"cells":70},"Humalog®",11,{"EARLY_PHASE1":71,"PHASE1":73,"PHASE2":165,"PHASE3":186,"PHASE4":188,"NA":190},{"trials":72,"activeCount":8},[],{"trials":74,"activeCount":8},[75,87,97,107,116,124,133,144,154],{"nctId":76,"briefTitle":77,"status":55,"phases":78,"primaryCompletion":79,"completion":79,"start":80,"enrollment":81,"conditions":82,"interventions":83},"NCT03916640","A Trial to Assess a Co-formulation of an Insulin Analog and Pramlintide in Subjects With Type 1 Diabetes Mellitus",[35],"2019-03-01","2019-01-04",24,[13],[84,85,86,68],"ADO09 formulation","Symlin®","Humulin®",{"nctId":88,"briefTitle":89,"status":55,"phases":90,"primaryCompletion":91,"completion":91,"start":92,"enrollment":93,"conditions":94,"interventions":95},"NCT02344992","Blood Glucose Control With BioChaperone Insulin Lispro Compared to Insulin Lispro (Humalog®) After Ingestion of a Standardized Meal",[35],"2015-06","2015-01",38,[16],[96,68],"BioChaperone insulin lispro",{"nctId":98,"briefTitle":99,"status":55,"phases":100,"primaryCompletion":101,"completion":102,"start":103,"enrollment":104,"conditions":105,"interventions":106},"NCT02029924","A Double-blinded, Randomised, Two -Period Crossover Euglycemic Clamp Trial Investigating the Pharmacokinetics, Glucodynamics and Safety of BioChaperone Insulin Lispro and Insulin Lispro (Humalog®) in Subjects With Type 1 Diabetes",[35],"2014-03","2014-08","2013-12",37,[16],[96,68],{"nctId":108,"briefTitle":109,"status":55,"phases":110,"primaryCompletion":111,"completion":111,"start":112,"enrollment":113,"conditions":114,"interventions":115},"NCT02562313","A Trial Investigating the Continuous Subcutaneous Insulin Infusion of a Liquid Formulation of BioChaperone Insulin Lispro in Comparison to Humalog®",[35],"2016-11","2015-09",80,[13],[96,68],{"nctId":117,"briefTitle":118,"status":55,"phases":119,"primaryCompletion":120,"completion":120,"start":112,"enrollment":121,"conditions":122,"interventions":123},"NCT02562326","A Trial to Investigate the Efficacy, Pharmacokinetics, Safety and Tolerability of BioChaperone Insulin Lispro in Comparison to Humalog® U-100 in Patients With Type 2 Diabetes Mellitus",[35],"2016-01",51,[19],[96,68],{"nctId":125,"briefTitle":126,"status":55,"phases":127,"primaryCompletion":128,"completion":128,"start":129,"enrollment":130,"conditions":131,"interventions":132},"NCT02528396","To Investigate the Efficacy and Safety of Individualized Doses of BioChaperone Insulin Lispro in Comparison to Humalog® U-100 in Patients With Type 1 Diabetes Mellitus",[35],"2015-12","2015-08",36,[13],[96,68],{"nctId":134,"briefTitle":135,"status":55,"phases":136,"primaryCompletion":137,"completion":137,"start":138,"enrollment":130,"conditions":139,"interventions":140},"NCT02915250","A Trial to Compare Post Prandial Blood Glucose Control of BioChaperone® Combo With Humalog® Mix25 and With Simultaneous Injections of Humalog® and Lantus® in Subjects With Type 2 Diabetes",[35],"2017-06","2016-10",[19],[141,142,68,143],"BioChaperone® Combo","Humalog® Mix25","Lantus®",{"nctId":145,"briefTitle":146,"status":55,"phases":147,"primaryCompletion":148,"completion":148,"start":149,"enrollment":81,"conditions":150,"interventions":151},"NCT03512236","A Trial to Investigate Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BioChaperone® Pramlintide Insulin in Patients With Type 1 Diabetes Mellitus",[35],"2019-02-14","2018-04-25",[13],[152,153,68],"BC Pram Ins","Symlin® and Humulin®",{"nctId":155,"briefTitle":156,"status":55,"phases":157,"primaryCompletion":158,"completion":158,"start":120,"enrollment":159,"conditions":160,"interventions":161},"NCT02660502","An Euglycemic Clamp Trial to Evaluate Pharmacokinetics of Single Doses of BioChaperone Insulin Lispro in Healthy Japanese Subjects",[35],"2016-05",15,[21],[162,163,164,68],"Biochaperone insulin lispro 0.1 U\u002Fkg","Biochaperone insulin lispro 0.2 U\u002Fkg","Biochaperone insulin lispro 0.4 U\u002Fkg",{"trials":166,"activeCount":8},[167,178],{"nctId":168,"briefTitle":169,"status":55,"phases":170,"primaryCompletion":171,"completion":58,"start":172,"enrollment":93,"conditions":173,"interventions":174},"NCT02146651","A Double-blinded, Randomised, Four-period Crossover Euglycemic Clamp Trial Investigating the Dose-response and Dose-exposure Relationship of BioChaperone Insulin Lispro in Three Different Doses in Subjects With Type 1 Diabetes",[36],"2014-07","2014-05",[16],[175,176,177,68],"BioChaperone insulin lispro 0.2U\u002FKg","BioChaperone insulin lispro 0.1U\u002FKg","BioChaperone insulin lispro 0.4U\u002FKg",{"nctId":179,"briefTitle":180,"status":55,"phases":181,"primaryCompletion":58,"completion":91,"start":102,"enrollment":93,"conditions":182,"interventions":183},"NCT02213146","A Double-blinded, Randomised, Three-period Crossover Euglycaemic Clamp Trial Investigating the Pharmacokinetics, Glucodynamics and Safety of BioChaperone Human Insulin, Human Insulin (Huminsulin® Normal) and Insulin Lispro (Humalog®) in Subjects With Type 1 Diabetes",[35,36],[16],[184,185,68],"BioChaperone human insulin","Huminsulin® Normal",{"trials":187,"activeCount":8},[],{"trials":189,"activeCount":8},[],{"trials":191,"activeCount":8},[],{"intervention":193,"totalTrials":22,"cells":194},"Insulin Lispro",{"EARLY_PHASE1":195,"PHASE1":197,"PHASE2":209,"PHASE3":230,"PHASE4":232,"NA":234},{"trials":196,"activeCount":8},[],{"trials":198,"activeCount":8},[199],{"nctId":200,"briefTitle":201,"status":55,"phases":202,"primaryCompletion":203,"completion":203,"start":204,"enrollment":104,"conditions":205,"interventions":207},"NCT01638325","A Study of Insulin Lispro With BioChaperone Excipient in Healthy Participants",[35],"2012-09","2012-07",[206],"Healthy Participants",[193,208],"BC106 insulin lispro",{"trials":210,"activeCount":8},[211,221],{"nctId":212,"briefTitle":213,"status":55,"phases":214,"primaryCompletion":215,"completion":215,"start":216,"enrollment":113,"conditions":217,"interventions":218},"NCT04816890","A Trial to Assess the Efficacy and Safety of M1 Pram P037 Prandial Insulin in Subjects With Type 1 Diabetes (T1DM)",[36],"2022-02-24","2021-03-23",[13],[219,220],"M1 Pram P037","Insulin lispro",{"nctId":222,"briefTitle":223,"status":55,"phases":224,"primaryCompletion":57,"completion":57,"start":225,"enrollment":130,"conditions":226,"interventions":227},"NCT02739906","A Trial to Investigate Post Prandial Blood Glucose Control With Fast-acting Human Insulin HinsBet® Compared to Insulin Lispro (Humalog®) and Regular Human Insulin (Huminsulin® Normal) After Ingestion of a Standardized Meal in Subjects With T1DM",[35,36],"2016-04",[13],[228,193,229],"BioChaperone Human Insulin","Regular human insulin",{"trials":231,"activeCount":8},[],{"trials":233,"activeCount":8},[],{"trials":235,"activeCount":8},[],{"intervention":84,"totalTrials":25,"cells":237},{"EARLY_PHASE1":238,"PHASE1":240,"PHASE2":246,"PHASE3":258,"PHASE4":260,"NA":262},{"trials":239,"activeCount":8},[],{"trials":241,"activeCount":8},[242],{"nctId":76,"briefTitle":77,"status":55,"phases":243,"primaryCompletion":79,"completion":79,"start":80,"enrollment":81,"conditions":244,"interventions":245},[35],[13],[84,85,86,68],{"trials":247,"activeCount":8},[248],{"nctId":249,"briefTitle":250,"status":55,"phases":251,"primaryCompletion":252,"completion":252,"start":253,"enrollment":254,"conditions":255,"interventions":256},"NCT03981627","A Trial to Assess Safety and Efficacy of ADO09 Versus Insulin Aspart in Subjects With Type 1 Diabetes Mellitus",[35,36],"2020-06-27","2019-06-06",44,[13],[84,257],"NovoRapid®",{"trials":259,"activeCount":8},[],{"trials":261,"activeCount":8},[],{"trials":263,"activeCount":8},[],{"intervention":265,"totalTrials":25,"cells":266},"Novorapid®",{"EARLY_PHASE1":267,"PHASE1":269,"PHASE2":283,"PHASE3":289,"PHASE4":291,"NA":293},{"trials":268,"activeCount":8},[],{"trials":270,"activeCount":8},[271],{"nctId":272,"briefTitle":273,"status":55,"phases":274,"primaryCompletion":275,"completion":275,"start":276,"enrollment":277,"conditions":278,"interventions":280},"NCT03179332","A Trial to Evaluate the Pharmacokinetic and Pharmacodynamic Properties of BioChaperone® Insulin Lispro, Fiasp® and NovoRapid® Delivered by an Insulin Pump",[35],"2017-09-27","2017-06-20",43,[279],"Type1 Diabetes Mellitus",[281,282,265],"BioChaperone® insulin lispro","Fiasp®",{"trials":284,"activeCount":8},[285],{"nctId":249,"briefTitle":250,"status":55,"phases":286,"primaryCompletion":252,"completion":252,"start":253,"enrollment":254,"conditions":287,"interventions":288},[35,36],[13],[84,257],{"trials":290,"activeCount":8},[],{"trials":292,"activeCount":8},[],{"trials":294,"activeCount":8},[],{"intervention":184,"totalTrials":25,"cells":296},{"EARLY_PHASE1":297,"PHASE1":299,"PHASE2":301,"PHASE3":311,"PHASE4":313,"NA":315},{"trials":298,"activeCount":8},[],{"trials":300,"activeCount":8},[],{"trials":302,"activeCount":8},[303,307],{"nctId":179,"briefTitle":180,"status":55,"phases":304,"primaryCompletion":58,"completion":91,"start":102,"enrollment":93,"conditions":305,"interventions":306},[35,36],[16],[184,185,68],{"nctId":222,"briefTitle":223,"status":55,"phases":308,"primaryCompletion":57,"completion":57,"start":225,"enrollment":130,"conditions":309,"interventions":310},[35,36],[13],[228,193,229],{"trials":312,"activeCount":8},[],{"trials":314,"activeCount":8},[],{"trials":316,"activeCount":8},[],{"intervention":175,"totalTrials":9,"cells":318},{"EARLY_PHASE1":319,"PHASE1":321,"PHASE2":323,"PHASE3":329,"PHASE4":331,"NA":333},{"trials":320,"activeCount":8},[],{"trials":322,"activeCount":8},[],{"trials":324,"activeCount":8},[325],{"nctId":168,"briefTitle":169,"status":55,"phases":326,"primaryCompletion":171,"completion":58,"start":172,"enrollment":93,"conditions":327,"interventions":328},[36],[16],[175,176,177,68],{"trials":330,"activeCount":8},[],{"trials":332,"activeCount":8},[],{"trials":334,"activeCount":8},[],{"intervention":176,"totalTrials":9,"cells":336},{"EARLY_PHASE1":337,"PHASE1":339,"PHASE2":341,"PHASE3":347,"PHASE4":349,"NA":351},{"trials":338,"activeCount":8},[],{"trials":340,"activeCount":8},[],{"trials":342,"activeCount":8},[343],{"nctId":168,"briefTitle":169,"status":55,"phases":344,"primaryCompletion":171,"completion":58,"start":172,"enrollment":93,"conditions":345,"interventions":346},[36],[16],[175,176,177,68],{"trials":348,"activeCount":8},[],{"trials":350,"activeCount":8},[],{"trials":352,"activeCount":8},[],{"intervention":177,"totalTrials":9,"cells":354},{"EARLY_PHASE1":355,"PHASE1":357,"PHASE2":359,"PHASE3":365,"PHASE4":367,"NA":369},{"trials":356,"activeCount":8},[],{"trials":358,"activeCount":8},[],{"trials":360,"activeCount":8},[361],{"nctId":168,"briefTitle":169,"status":55,"phases":362,"primaryCompletion":171,"completion":58,"start":172,"enrollment":93,"conditions":363,"interventions":364},[36],[16],[175,176,177,68],{"trials":366,"activeCount":8},[],{"trials":368,"activeCount":8},[],{"trials":370,"activeCount":8},[],{"intervention":185,"totalTrials":9,"cells":372},{"EARLY_PHASE1":373,"PHASE1":375,"PHASE2":377,"PHASE3":383,"PHASE4":385,"NA":387},{"trials":374,"activeCount":8},[],{"trials":376,"activeCount":8},[],{"trials":378,"activeCount":8},[379],{"nctId":179,"briefTitle":180,"status":55,"phases":380,"primaryCompletion":58,"completion":91,"start":102,"enrollment":93,"conditions":381,"interventions":382},[35,36],[16],[184,185,68],{"trials":384,"activeCount":8},[],{"trials":386,"activeCount":8},[],{"trials":388,"activeCount":8},[],{"intervention":219,"totalTrials":9,"cells":390},{"EARLY_PHASE1":391,"PHASE1":393,"PHASE2":395,"PHASE3":401,"PHASE4":403,"NA":405},{"trials":392,"activeCount":8},[],{"trials":394,"activeCount":8},[],{"trials":396,"activeCount":8},[397],{"nctId":212,"briefTitle":213,"status":55,"phases":398,"primaryCompletion":215,"completion":215,"start":216,"enrollment":113,"conditions":399,"interventions":400},[36],[13],[219,220],{"trials":402,"activeCount":8},[],{"trials":404,"activeCount":8},[],{"trials":406,"activeCount":8},[],{"intervention":229,"totalTrials":9,"cells":408},{"EARLY_PHASE1":409,"PHASE1":411,"PHASE2":413,"PHASE3":419,"PHASE4":421,"NA":423},{"trials":410,"activeCount":8},[],{"trials":412,"activeCount":8},[],{"trials":414,"activeCount":8},[415],{"nctId":222,"briefTitle":223,"status":55,"phases":416,"primaryCompletion":57,"completion":57,"start":225,"enrollment":130,"conditions":417,"interventions":418},[35,36],[13],[228,193,229],{"trials":420,"activeCount":8},[],{"trials":422,"activeCount":8},[],{"trials":424,"activeCount":8},[],{"intervention":96,"totalTrials":426,"cells":427},5,{"EARLY_PHASE1":428,"PHASE1":430,"PHASE2":452,"PHASE3":454,"PHASE4":456,"NA":458},{"trials":429,"activeCount":8},[],{"trials":431,"activeCount":8},[432,436,440,444,448],{"nctId":88,"briefTitle":89,"status":55,"phases":433,"primaryCompletion":91,"completion":91,"start":92,"enrollment":93,"conditions":434,"interventions":435},[35],[16],[96,68],{"nctId":98,"briefTitle":99,"status":55,"phases":437,"primaryCompletion":101,"completion":102,"start":103,"enrollment":104,"conditions":438,"interventions":439},[35],[16],[96,68],{"nctId":108,"briefTitle":109,"status":55,"phases":441,"primaryCompletion":111,"completion":111,"start":112,"enrollment":113,"conditions":442,"interventions":443},[35],[13],[96,68],{"nctId":117,"briefTitle":118,"status":55,"phases":445,"primaryCompletion":120,"completion":120,"start":112,"enrollment":121,"conditions":446,"interventions":447},[35],[19],[96,68],{"nctId":125,"briefTitle":126,"status":55,"phases":449,"primaryCompletion":128,"completion":128,"start":129,"enrollment":130,"conditions":450,"interventions":451},[35],[13],[96,68],{"trials":453,"activeCount":8},[],{"trials":455,"activeCount":8},[],{"trials":457,"activeCount":8},[],{"trials":459,"activeCount":8},[],{"intervention":461,"totalTrials":22,"cells":462},"Euglycemic clamp with BC Combo THDB0207",{"EARLY_PHASE1":463,"PHASE1":465,"PHASE2":495,"PHASE3":497,"PHASE4":499,"NA":501},{"trials":464,"activeCount":8},[],{"trials":466,"activeCount":8},[467,477,485],{"nctId":468,"briefTitle":469,"status":55,"phases":470,"primaryCompletion":471,"completion":471,"start":472,"enrollment":473,"conditions":474,"interventions":475},"NCT05373212","A Trial Investigating the Dose Linearity and Safety of BC Combo THDB0207 in Subjects With Type 2 Diabetes",[35],"2023-01-02","2022-05-12",40,[27],[461,476],"Euglycemic clamp with Humalog® Mix25",{"nctId":478,"briefTitle":479,"status":55,"phases":480,"primaryCompletion":481,"completion":481,"start":472,"enrollment":6,"conditions":482,"interventions":483},"NCT05373186","A Trial Investigating the Pharmacodynamics of BC Combo THDB0207 Compared With Humalog® Mix25 and Simultaneous Injections of Humalog® and Lantus® in Healthy Chinese Volunteers",[35],"2022-12-04",[21],[461,476,484],"Euglycemic clamp with Humalog® and Lantus®",{"nctId":486,"briefTitle":487,"status":55,"phases":488,"primaryCompletion":489,"completion":489,"start":472,"enrollment":490,"conditions":491,"interventions":492},"NCT05373199","A Trial Comparing the Pharmacodynamics and Pharmacokinetics of BC Combo THDB0207 and Lantus® and Humalog® in Subjects With Type 1 Diabetes",[35],"2022-10-28",30,[24],[461,493,494],"Euglycemic clamp with Lantus®","Euglycemic clamp with Humalog®",{"trials":496,"activeCount":8},[],{"trials":498,"activeCount":8},[],{"trials":500,"activeCount":8},[],{"trials":502,"activeCount":8},[],{"intervention":141,"totalTrials":22,"cells":504},{"EARLY_PHASE1":505,"PHASE1":507,"PHASE2":531,"PHASE3":533,"PHASE4":535,"NA":537},{"trials":506,"activeCount":8},[],{"trials":508,"activeCount":8},[509,517,527],{"nctId":510,"briefTitle":511,"status":55,"phases":512,"primaryCompletion":103,"completion":102,"start":513,"enrollment":514,"conditions":515,"interventions":516},"NCT01981031","A Trial to Assess the Efficacy and Safety of BioChaperone Combo and Humalog Mix 25 in Subjects With Type 1 Diabetes",[35],"2013-11",21,[29,31],[141,142],{"nctId":518,"briefTitle":519,"status":55,"phases":520,"primaryCompletion":521,"completion":521,"start":522,"enrollment":523,"conditions":524,"interventions":525},"NCT02514954","Postprandial Blood Glucose Control With BioChaperone® Combo and Insulin Lispro (Humalog®) Mix 25 in People With Type 1 Diabetes Mellitus",[35],"2015-11","2015-07",28,[13],[526,142],"Biochaperone® Combo",{"nctId":134,"briefTitle":135,"status":55,"phases":528,"primaryCompletion":137,"completion":137,"start":138,"enrollment":130,"conditions":529,"interventions":530},[35],[19],[141,142,68,143],{"trials":532,"activeCount":8},[],{"trials":534,"activeCount":8},[],{"trials":536,"activeCount":8},[],{"trials":538,"activeCount":8},[],{"intervention":142,"totalTrials":22,"cells":540},{"EARLY_PHASE1":541,"PHASE1":543,"PHASE2":557,"PHASE3":559,"PHASE4":561,"NA":563},{"trials":542,"activeCount":8},[],{"trials":544,"activeCount":8},[545,549,553],{"nctId":510,"briefTitle":511,"status":55,"phases":546,"primaryCompletion":103,"completion":102,"start":513,"enrollment":514,"conditions":547,"interventions":548},[35],[29,31],[141,142],{"nctId":518,"briefTitle":519,"status":55,"phases":550,"primaryCompletion":521,"completion":521,"start":522,"enrollment":523,"conditions":551,"interventions":552},[35],[13],[526,142],{"nctId":134,"briefTitle":135,"status":55,"phases":554,"primaryCompletion":137,"completion":137,"start":138,"enrollment":130,"conditions":555,"interventions":556},[35],[19],[141,142,68,143],{"trials":558,"activeCount":8},[],{"trials":560,"activeCount":8},[],{"trials":562,"activeCount":8},[],{"trials":564,"activeCount":8},[],{"intervention":476,"totalTrials":25,"cells":566},{"EARLY_PHASE1":567,"PHASE1":569,"PHASE2":579,"PHASE3":581,"PHASE4":583,"NA":585},{"trials":568,"activeCount":8},[],{"trials":570,"activeCount":8},[571,575],{"nctId":468,"briefTitle":469,"status":55,"phases":572,"primaryCompletion":471,"completion":471,"start":472,"enrollment":473,"conditions":573,"interventions":574},[35],[27],[461,476],{"nctId":478,"briefTitle":479,"status":55,"phases":576,"primaryCompletion":481,"completion":481,"start":472,"enrollment":6,"conditions":577,"interventions":578},[35],[21],[461,476,484],{"trials":580,"activeCount":8},[],{"trials":582,"activeCount":8},[],{"trials":584,"activeCount":8},[],{"trials":586,"activeCount":8},[],{"intervention":588,"totalTrials":9,"cells":589},"BioChaperone® glucagon formulation 1",{"EARLY_PHASE1":590,"PHASE1":592,"PHASE2":604,"PHASE3":606,"PHASE4":608,"NA":610},{"trials":591,"activeCount":8},[],{"trials":593,"activeCount":8},[594],{"nctId":595,"briefTitle":596,"status":55,"phases":597,"primaryCompletion":598,"completion":598,"start":599,"enrollment":6,"conditions":600,"interventions":601},"NCT03176524","A Trial to Investigate the Safety and the Pharmacokinetic, Pharmacodynamic Characteristics of Two BioChaperone® Glucagon Formulations Compared to Marketed GlucaGen® in Subjects With T1DM",[35],"2017-09-04","2017-06-06",[13],[588,602,603],"BioChaperone® glucagon formulation 2","GlucaGen® HypoKit®",{"trials":605,"activeCount":8},[],{"trials":607,"activeCount":8},[],{"trials":609,"activeCount":8},[],{"trials":611,"activeCount":8},[],{"intervention":602,"totalTrials":9,"cells":613},{"EARLY_PHASE1":614,"PHASE1":616,"PHASE2":622,"PHASE3":624,"PHASE4":626,"NA":628},{"trials":615,"activeCount":8},[],{"trials":617,"activeCount":8},[618],{"nctId":595,"briefTitle":596,"status":55,"phases":619,"primaryCompletion":598,"completion":598,"start":599,"enrollment":6,"conditions":620,"interventions":621},[35],[13],[588,602,603],{"trials":623,"activeCount":8},[],{"trials":625,"activeCount":8},[],{"trials":627,"activeCount":8},[],{"trials":629,"activeCount":8},[],{"intervention":603,"totalTrials":9,"cells":631},{"EARLY_PHASE1":632,"PHASE1":634,"PHASE2":640,"PHASE3":642,"PHASE4":644,"NA":646},{"trials":633,"activeCount":8},[],{"trials":635,"activeCount":8},[636],{"nctId":595,"briefTitle":596,"status":55,"phases":637,"primaryCompletion":598,"completion":598,"start":599,"enrollment":6,"conditions":638,"interventions":639},[35],[13],[588,602,603],{"trials":641,"activeCount":8},[],{"trials":643,"activeCount":8},[],{"trials":645,"activeCount":8},[],{"trials":647,"activeCount":8},[],{"intervention":85,"totalTrials":9,"cells":649},{"EARLY_PHASE1":650,"PHASE1":652,"PHASE2":658,"PHASE3":660,"PHASE4":662,"NA":664},{"trials":651,"activeCount":8},[],{"trials":653,"activeCount":8},[654],{"nctId":76,"briefTitle":77,"status":55,"phases":655,"primaryCompletion":79,"completion":79,"start":80,"enrollment":81,"conditions":656,"interventions":657},[35],[13],[84,85,86,68],{"trials":659,"activeCount":8},[],{"trials":661,"activeCount":8},[],{"trials":663,"activeCount":8},[],{"trials":665,"activeCount":8},[],{"intervention":86,"totalTrials":9,"cells":667},{"EARLY_PHASE1":668,"PHASE1":670,"PHASE2":676,"PHASE3":678,"PHASE4":680,"NA":682},{"trials":669,"activeCount":8},[],{"trials":671,"activeCount":8},[672],{"nctId":76,"briefTitle":77,"status":55,"phases":673,"primaryCompletion":79,"completion":79,"start":80,"enrollment":81,"conditions":674,"interventions":675},[35],[13],[84,85,86,68],{"trials":677,"activeCount":8},[],{"trials":679,"activeCount":8},[],{"trials":681,"activeCount":8},[],{"trials":683,"activeCount":8},[],{"intervention":484,"totalTrials":9,"cells":685},{"EARLY_PHASE1":686,"PHASE1":688,"PHASE2":694,"PHASE3":696,"PHASE4":698,"NA":700},{"trials":687,"activeCount":8},[],{"trials":689,"activeCount":8},[690],{"nctId":478,"briefTitle":479,"status":55,"phases":691,"primaryCompletion":481,"completion":481,"start":472,"enrollment":6,"conditions":692,"interventions":693},[35],[21],[461,476,484],{"trials":695,"activeCount":8},[],{"trials":697,"activeCount":8},[],{"trials":699,"activeCount":8},[],{"trials":701,"activeCount":8},[],{"intervention":281,"totalTrials":9,"cells":703},{"EARLY_PHASE1":704,"PHASE1":706,"PHASE2":712,"PHASE3":714,"PHASE4":716,"NA":718},{"trials":705,"activeCount":8},[],{"trials":707,"activeCount":8},[708],{"nctId":272,"briefTitle":273,"status":55,"phases":709,"primaryCompletion":275,"completion":275,"start":276,"enrollment":277,"conditions":710,"interventions":711},[35],[279],[281,282,265],{"trials":713,"activeCount":8},[],{"trials":715,"activeCount":8},[],{"trials":717,"activeCount":8},[],{"trials":719,"activeCount":8},[],{"intervention":282,"totalTrials":9,"cells":721},{"EARLY_PHASE1":722,"PHASE1":724,"PHASE2":730,"PHASE3":732,"PHASE4":734,"NA":736},{"trials":723,"activeCount":8},[],{"trials":725,"activeCount":8},[726],{"nctId":272,"briefTitle":273,"status":55,"phases":727,"primaryCompletion":275,"completion":275,"start":276,"enrollment":277,"conditions":728,"interventions":729},[35],[279],[281,282,265],{"trials":731,"activeCount":8},[],{"trials":733,"activeCount":8},[],{"trials":735,"activeCount":8},[],{"trials":737,"activeCount":8},[],{"intervention":493,"totalTrials":9,"cells":739},{"EARLY_PHASE1":740,"PHASE1":742,"PHASE2":748,"PHASE3":750,"PHASE4":752,"NA":754},{"trials":741,"activeCount":8},[],{"trials":743,"activeCount":8},[744],{"nctId":486,"briefTitle":487,"status":55,"phases":745,"primaryCompletion":489,"completion":489,"start":472,"enrollment":490,"conditions":746,"interventions":747},[35],[24],[461,493,494],{"trials":749,"activeCount":8},[],{"trials":751,"activeCount":8},[],{"trials":753,"activeCount":8},[],{"trials":755,"activeCount":8},[],{"intervention":494,"totalTrials":9,"cells":757},{"EARLY_PHASE1":758,"PHASE1":760,"PHASE2":766,"PHASE3":768,"PHASE4":770,"NA":772},{"trials":759,"activeCount":8},[],{"trials":761,"activeCount":8},[762],{"nctId":486,"briefTitle":487,"status":55,"phases":763,"primaryCompletion":489,"completion":489,"start":472,"enrollment":490,"conditions":764,"interventions":765},[35],[24],[461,493,494],{"trials":767,"activeCount":8},[],{"trials":769,"activeCount":8},[],{"trials":771,"activeCount":8},[],{"trials":773,"activeCount":8},[],{"intervention":775,"totalTrials":9,"cells":776},"BioChaperone Lispro U-100",{"EARLY_PHASE1":777,"PHASE1":779,"PHASE2":789,"PHASE3":791,"PHASE4":793,"NA":795},{"trials":778,"activeCount":8},[],{"trials":780,"activeCount":8},[781],{"nctId":782,"briefTitle":783,"status":55,"phases":784,"primaryCompletion":521,"completion":521,"start":129,"enrollment":785,"conditions":786,"interventions":787},"NCT02529293","A Clinical Trial Investigating the Intra-subject Variability of Pharmacokinetics and Glucodynamics of BioChaperone Insulin Lispro U-100 Product and U-200 Product in Healthy Volunteers",[35],26,[21],[775,788],"BioChaperone Lispro U-200",{"trials":790,"activeCount":8},[],{"trials":792,"activeCount":8},[],{"trials":794,"activeCount":8},[],{"trials":796,"activeCount":8},[],{"intervention":788,"totalTrials":9,"cells":798},{"EARLY_PHASE1":799,"PHASE1":801,"PHASE2":807,"PHASE3":809,"PHASE4":811,"NA":813},{"trials":800,"activeCount":8},[],{"trials":802,"activeCount":8},[803],{"nctId":782,"briefTitle":783,"status":55,"phases":804,"primaryCompletion":521,"completion":521,"start":129,"enrollment":785,"conditions":805,"interventions":806},[35],[21],[775,788],{"trials":808,"activeCount":8},[],{"trials":810,"activeCount":8},[],{"trials":812,"activeCount":8},[],{"trials":814,"activeCount":8},[],{"intervention":143,"totalTrials":9,"cells":816},{"EARLY_PHASE1":817,"PHASE1":819,"PHASE2":825,"PHASE3":827,"PHASE4":829,"NA":831},{"trials":818,"activeCount":8},[],{"trials":820,"activeCount":8},[821],{"nctId":134,"briefTitle":135,"status":55,"phases":822,"primaryCompletion":137,"completion":137,"start":138,"enrollment":130,"conditions":823,"interventions":824},[35],[19],[141,142,68,143],{"trials":826,"activeCount":8},[],{"trials":828,"activeCount":8},[],{"trials":830,"activeCount":8},[],{"trials":832,"activeCount":8},[],{"intervention":834,"totalTrials":9,"cells":835},"Administration of BioChaperone insulin lispro reconstituted with Humalog®",{"EARLY_PHASE1":836,"PHASE1":838,"PHASE2":852,"PHASE3":854,"PHASE4":856,"NA":858},{"trials":837,"activeCount":8},[],{"trials":839,"activeCount":8},[840],{"nctId":841,"briefTitle":842,"status":55,"phases":843,"primaryCompletion":844,"completion":844,"start":845,"enrollment":846,"conditions":847,"interventions":848},"NCT04501107","A Trial to Compare BioChaperone Insulin Lispro Formulations With US Approved Humalog® and With EU Approved Humalog® in Patients With Type 1 Diabetes Mellitus",[35],"2020-11-03","2020-08-03",32,[24],[834,849,850,851],"Administration of Ready-to-use BioChaperone insulin lispro","Administration of US-approved Humalog®","Administration of EU-approved Humalog®",{"trials":853,"activeCount":8},[],{"trials":855,"activeCount":8},[],{"trials":857,"activeCount":8},[],{"trials":859,"activeCount":8},[],{"intervention":849,"totalTrials":9,"cells":861},{"EARLY_PHASE1":862,"PHASE1":864,"PHASE2":870,"PHASE3":872,"PHASE4":874,"NA":876},{"trials":863,"activeCount":8},[],{"trials":865,"activeCount":8},[866],{"nctId":841,"briefTitle":842,"status":55,"phases":867,"primaryCompletion":844,"completion":844,"start":845,"enrollment":846,"conditions":868,"interventions":869},[35],[24],[834,849,850,851],{"trials":871,"activeCount":8},[],{"trials":873,"activeCount":8},[],{"trials":875,"activeCount":8},[],{"trials":877,"activeCount":8},[],{"intervention":850,"totalTrials":9,"cells":879},{"EARLY_PHASE1":880,"PHASE1":882,"PHASE2":888,"PHASE3":890,"PHASE4":892,"NA":894},{"trials":881,"activeCount":8},[],{"trials":883,"activeCount":8},[884],{"nctId":841,"briefTitle":842,"status":55,"phases":885,"primaryCompletion":844,"completion":844,"start":845,"enrollment":846,"conditions":886,"interventions":887},[35],[24],[834,849,850,851],{"trials":889,"activeCount":8},[],{"trials":891,"activeCount":8},[],{"trials":893,"activeCount":8},[],{"trials":895,"activeCount":8},[],{"intervention":851,"totalTrials":9,"cells":897},{"EARLY_PHASE1":898,"PHASE1":900,"PHASE2":906,"PHASE3":908,"PHASE4":910,"NA":912},{"trials":899,"activeCount":8},[],{"trials":901,"activeCount":8},[902],{"nctId":841,"briefTitle":842,"status":55,"phases":903,"primaryCompletion":844,"completion":844,"start":845,"enrollment":846,"conditions":904,"interventions":905},[35],[24],[834,849,850,851],{"trials":907,"activeCount":8},[],{"trials":909,"activeCount":8},[],{"trials":911,"activeCount":8},[],{"trials":913,"activeCount":8},[],{"intervention":152,"totalTrials":9,"cells":915},{"EARLY_PHASE1":916,"PHASE1":918,"PHASE2":924,"PHASE3":926,"PHASE4":928,"NA":930},{"trials":917,"activeCount":8},[],{"trials":919,"activeCount":8},[920],{"nctId":145,"briefTitle":146,"status":55,"phases":921,"primaryCompletion":148,"completion":148,"start":149,"enrollment":81,"conditions":922,"interventions":923},[35],[13],[152,153,68],{"trials":925,"activeCount":8},[],{"trials":927,"activeCount":8},[],{"trials":929,"activeCount":8},[],{"trials":931,"activeCount":8},[],{"intervention":153,"totalTrials":9,"cells":933},{"EARLY_PHASE1":934,"PHASE1":936,"PHASE2":942,"PHASE3":944,"PHASE4":946,"NA":948},{"trials":935,"activeCount":8},[],{"trials":937,"activeCount":8},[938],{"nctId":145,"briefTitle":146,"status":55,"phases":939,"primaryCompletion":148,"completion":148,"start":149,"enrollment":81,"conditions":940,"interventions":941},[35],[13],[152,153,68],{"trials":943,"activeCount":8},[],{"trials":945,"activeCount":8},[],{"trials":947,"activeCount":8},[],{"trials":949,"activeCount":8},[],{"intervention":951,"totalTrials":9,"cells":952},"Biochaperone Combo",{"EARLY_PHASE1":953,"PHASE1":955,"PHASE2":966,"PHASE3":968,"PHASE4":970,"NA":972},{"trials":954,"activeCount":8},[],{"trials":956,"activeCount":8},[957],{"nctId":958,"briefTitle":959,"status":55,"phases":960,"primaryCompletion":521,"completion":521,"start":522,"enrollment":81,"conditions":961,"interventions":962},"NCT02514850","A Trial to Compare the Pharmacodynamic and Pharmacokinetic Properties of Biochaperone® Combo With Humalog® Mix25 and With Simultaneous Injections of Humalog® and Lantus® in Subjects With Type 2 Diabetes",[35],[19],[951,963,964,965],"Humalog Mix25","Humalog","Lantus",{"trials":967,"activeCount":8},[],{"trials":969,"activeCount":8},[],{"trials":971,"activeCount":8},[],{"trials":973,"activeCount":8},[],{"intervention":963,"totalTrials":9,"cells":975},{"EARLY_PHASE1":976,"PHASE1":978,"PHASE2":984,"PHASE3":986,"PHASE4":988,"NA":990},{"trials":977,"activeCount":8},[],{"trials":979,"activeCount":8},[980],{"nctId":958,"briefTitle":959,"status":55,"phases":981,"primaryCompletion":521,"completion":521,"start":522,"enrollment":81,"conditions":982,"interventions":983},[35],[19],[951,963,964,965],{"trials":985,"activeCount":8},[],{"trials":987,"activeCount":8},[],{"trials":989,"activeCount":8},[],{"trials":991,"activeCount":8},[],{"intervention":964,"totalTrials":9,"cells":993},{"EARLY_PHASE1":994,"PHASE1":996,"PHASE2":1002,"PHASE3":1004,"PHASE4":1006,"NA":1008},{"trials":995,"activeCount":8},[],{"trials":997,"activeCount":8},[998],{"nctId":958,"briefTitle":959,"status":55,"phases":999,"primaryCompletion":521,"completion":521,"start":522,"enrollment":81,"conditions":1000,"interventions":1001},[35],[19],[951,963,964,965],{"trials":1003,"activeCount":8},[],{"trials":1005,"activeCount":8},[],{"trials":1007,"activeCount":8},[],{"trials":1009,"activeCount":8},[],{"intervention":965,"totalTrials":9,"cells":1011},{"EARLY_PHASE1":1012,"PHASE1":1014,"PHASE2":1020,"PHASE3":1022,"PHASE4":1024,"NA":1026},{"trials":1013,"activeCount":8},[],{"trials":1015,"activeCount":8},[1016],{"nctId":958,"briefTitle":959,"status":55,"phases":1017,"primaryCompletion":521,"completion":521,"start":522,"enrollment":81,"conditions":1018,"interventions":1019},[35],[19],[951,963,964,965],{"trials":1021,"activeCount":8},[],{"trials":1023,"activeCount":8},[],{"trials":1025,"activeCount":8},[],{"trials":1027,"activeCount":8},[],{"intervention":208,"totalTrials":9,"cells":1029},{"EARLY_PHASE1":1030,"PHASE1":1032,"PHASE2":1038,"PHASE3":1040,"PHASE4":1042,"NA":1044},{"trials":1031,"activeCount":8},[],{"trials":1033,"activeCount":8},[1034],{"nctId":200,"briefTitle":201,"status":55,"phases":1035,"primaryCompletion":203,"completion":203,"start":204,"enrollment":104,"conditions":1036,"interventions":1037},[35],[206],[193,208],{"trials":1039,"activeCount":8},[],{"trials":1041,"activeCount":8},[],{"trials":1043,"activeCount":8},[],{"trials":1045,"activeCount":8},[],{"intervention":1047,"totalTrials":9,"cells":1048},"BioChaperone® Combo 75\u002F25 at 0.6 U\u002Fkg",{"EARLY_PHASE1":1049,"PHASE1":1051,"PHASE2":1064,"PHASE3":1066,"PHASE4":1068,"NA":1070},{"trials":1050,"activeCount":8},[],{"trials":1052,"activeCount":8},[1053],{"nctId":1054,"briefTitle":1055,"status":55,"phases":1056,"primaryCompletion":1057,"completion":1058,"start":599,"enrollment":846,"conditions":1059,"interventions":1060},"NCT03180710","A Trial to Investigate the Dose-linearity of BioChaperone® Combo 75\u002F25 and the Safety at Three Different Doses in Subjects With Type 2 Diabetes",[35],"2017-08-28","2017-12-21",[19],[1047,1061,1062,1063],"BioChaperone® Combo 75\u002F25 at 0.8 U\u002Fkg","BioChaperone® Combo 75\u002F25 at 1.0 U\u002Fkg","Humalog® Mix25 at 0.8 U\u002Fkg",{"trials":1065,"activeCount":8},[],{"trials":1067,"activeCount":8},[],{"trials":1069,"activeCount":8},[],{"trials":1071,"activeCount":8},[],{"intervention":1061,"totalTrials":9,"cells":1073},{"EARLY_PHASE1":1074,"PHASE1":1076,"PHASE2":1082,"PHASE3":1084,"PHASE4":1086,"NA":1088},{"trials":1075,"activeCount":8},[],{"trials":1077,"activeCount":8},[1078],{"nctId":1054,"briefTitle":1055,"status":55,"phases":1079,"primaryCompletion":1057,"completion":1058,"start":599,"enrollment":846,"conditions":1080,"interventions":1081},[35],[19],[1047,1061,1062,1063],{"trials":1083,"activeCount":8},[],{"trials":1085,"activeCount":8},[],{"trials":1087,"activeCount":8},[],{"trials":1089,"activeCount":8},[],{"intervention":1062,"totalTrials":9,"cells":1091},{"EARLY_PHASE1":1092,"PHASE1":1094,"PHASE2":1100,"PHASE3":1102,"PHASE4":1104,"NA":1106},{"trials":1093,"activeCount":8},[],{"trials":1095,"activeCount":8},[1096],{"nctId":1054,"briefTitle":1055,"status":55,"phases":1097,"primaryCompletion":1057,"completion":1058,"start":599,"enrollment":846,"conditions":1098,"interventions":1099},[35],[19],[1047,1061,1062,1063],{"trials":1101,"activeCount":8},[],{"trials":1103,"activeCount":8},[],{"trials":1105,"activeCount":8},[],{"trials":1107,"activeCount":8},[],{"intervention":1063,"totalTrials":9,"cells":1109},{"EARLY_PHASE1":1110,"PHASE1":1112,"PHASE2":1118,"PHASE3":1120,"PHASE4":1122,"NA":1124},{"trials":1111,"activeCount":8},[],{"trials":1113,"activeCount":8},[1114],{"nctId":1054,"briefTitle":1055,"status":55,"phases":1115,"primaryCompletion":1057,"completion":1058,"start":599,"enrollment":846,"conditions":1116,"interventions":1117},[35],[19],[1047,1061,1062,1063],{"trials":1119,"activeCount":8},[],{"trials":1121,"activeCount":8},[],{"trials":1123,"activeCount":8},[],{"trials":1125,"activeCount":8},[],{"intervention":162,"totalTrials":9,"cells":1127},{"EARLY_PHASE1":1128,"PHASE1":1130,"PHASE2":1136,"PHASE3":1138,"PHASE4":1140,"NA":1142},{"trials":1129,"activeCount":8},[],{"trials":1131,"activeCount":8},[1132],{"nctId":155,"briefTitle":156,"status":55,"phases":1133,"primaryCompletion":158,"completion":158,"start":120,"enrollment":159,"conditions":1134,"interventions":1135},[35],[21],[162,163,164,68],{"trials":1137,"activeCount":8},[],{"trials":1139,"activeCount":8},[],{"trials":1141,"activeCount":8},[],{"trials":1143,"activeCount":8},[],{"intervention":163,"totalTrials":9,"cells":1145},{"EARLY_PHASE1":1146,"PHASE1":1148,"PHASE2":1154,"PHASE3":1156,"PHASE4":1158,"NA":1160},{"trials":1147,"activeCount":8},[],{"trials":1149,"activeCount":8},[1150],{"nctId":155,"briefTitle":156,"status":55,"phases":1151,"primaryCompletion":158,"completion":158,"start":120,"enrollment":159,"conditions":1152,"interventions":1153},[35],[21],[162,163,164,68],{"trials":1155,"activeCount":8},[],{"trials":1157,"activeCount":8},[],{"trials":1159,"activeCount":8},[],{"trials":1161,"activeCount":8},[],{"intervention":164,"totalTrials":9,"cells":1163},{"EARLY_PHASE1":1164,"PHASE1":1166,"PHASE2":1172,"PHASE3":1174,"PHASE4":1176,"NA":1178},{"trials":1165,"activeCount":8},[],{"trials":1167,"activeCount":8},[1168],{"nctId":155,"briefTitle":156,"status":55,"phases":1169,"primaryCompletion":158,"completion":158,"start":120,"enrollment":159,"conditions":1170,"interventions":1171},[35],[21],[162,163,164,68],{"trials":1173,"activeCount":8},[],{"trials":1175,"activeCount":8},[],{"trials":1177,"activeCount":8},[],{"trials":1179,"activeCount":8},[]]